Lior Sheinfeld, 052-5344011
Contemporary research in second consciousness materials
During the last 30 years the MA organization . PS Promotes research into various psychedelic substances.
The most advanced research is MDMA-based therapy (the active substance in ecstasy) for victims suffering from post-traumatic stress disorder (MDMA Assisted Psychotherapy for PTSD) which is held in several countries in the world, including Israel. The third and final phase of the study has been completed these days and is before the approval of the FDA, which in 2017 declared this treatment a "breakthrough treatment" in light of results that showed that one year after the end of the treatment, 68% of the participants no longer suffered from symptoms at the level defined as post-traumatic stress disorder. Of the remaining 32%, a large proportion showed marked improvement in symptoms but were still defined as having post-traumatic symptoms. During the treatment, which lasts 12 sessions, the patient is accompanied by two therapists specially trained for this treatment, when only in 3 of the sessions the patient takes the MDMA, under controlled conditions (see Set and Sting ).
There are many other studies, most of which are on the effect of psilocybin, the active ingredient in hallucinogenic mushrooms. This is a substance that shows extremely high neuroplasticity (the ability to change brain structures). The leading studies, conducted by researchers at Johns Hopkins University, California and New York, focus on dealing with resistant depression and meanwhile show promising results, until in 2019 the FDA declared psilocybin-based therapy as a "breakthrough treatment" (see article here) in resistant depression. Additional studies show promising results also among terminally ill patients, where an improvement in their well being was reported during the remaining time of their lives.
The research field deals a lot with the potential inherent in these materials and several conferences were recently held on the subject.
It is recommended to be impressed by the lecture of Dr. Rick Dublin , founder of the MAPS organization, in which he explains about the field.